Human VISTA Antibody - Onvatilimab IgG1fut Isotype

Human IgG1, non-fucosylated

ABOUT

Non-fucosylated human IgG1 monoclonal antibody (mAb) against human VISTA

Anti-hVISTA-hIgG1fut is a recombinant monoclonal antibody (mAb) featuring a variable region that recognizes human VISTA, a member of the CD28/B7 protein superfamily, and a non-fucosylated constant region of the human IgG1 (hIgG1fut) isotype.

V-domain Ig-containing suppressor of T-cell activation (VISTA), also known as programmed death-1 homolog (PH-1H) is a known immune checkpoint, that directly suppresses T cell activation, proliferation, and cytokine production [1]. VISTA can be considered both a ligand and a receptor, whereby it transmits inhibitory signals to T cells, either extrinsically, through expression on myeloid cells (i.e. macrophage and dendritic cells) and binding to an unknown receptor on T cells, or intrinsically, through its expression on T cells (i.e. CD4+, CD8+) [2]. In the context of cancer immunotherapy, VISTA has been found to be heightened on cells that infiltrate the tumor microenvironment (TME) and not the tumor cells themselves, therefore, VISTA-blocking antibodies are of interest. These function to inhibit the engagement of VISTA with its receptor on T cells or by directly targeting VISTA expressed on naïve and effector T cells, preventing it from providing negative signaling [1, 2].

Features of Anti-hVISTA-hIgG1fut:

  • Targets specifically human VISTA
  • Features the hIgG1fut constant region for enhanced effector function
  • Functionally validated by flow cytometry

Anti-hVISTA-hIgG1fut is a non-fucosylated antibody, whereby the absence of fucose residues from N-glycans of the IgG-Fc results in an enhancement of antibody-dependent cellular cytotoxicity (ADCC). This increased ADCC is without any detectable change to complement-dependent cytotoxicity (CDC) or antigen-binding capability. Anti-hVISTA-hIgG1fut was generated by recombinant DNA technology, produced in CHO cells (deficient for fucosylation), and purified by affinity chromatography with protein G.

 

References:

1. Nowak, E.C. et al. 2017. Immunoregulatory functions of VISTA. Immunol Rev 276, 66-79.
2. Xu, W. et al. 2018. The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation. Cell Mol Immunol 15, 438-446.

All products are for research use only, and not for human or veterinary use.

SPECIFICATIONS

Specifications

Target

V-domain Ig containing suppressor of T-cell activation (VISTA)

Target species

Human

Applications

Anti-hVSITA-hIgG1fut binds and blocks ligand activation of the VISTA receptor found on the surface of cells

Isotype
hIgG1fut
kappa
Source
CHO cells
Purification
Protein G
Formulation buffer

0.2 μm filtered solution in a sodium phosphate buffer with glycine, saccharose, and stabilizing agents.

Preservative
Azide-free
Aggregation

< 5%

Reconstitution buffer
Sterile water
Sterility

Absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and TLR4 cellular assays.

Endotoxin

Negative (tested using EndotoxDetect™ assay)

Tested applications

ADCC assay, Flow cytometry

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Anti-hVISTA-hIgG1fut
  • Cat code: 
    hvista-mab13
  • Quantity: 
    100 µg

Shipping & Storage

  • Shipping method:  Room temperature
  • Storage:

    • -20°C
    Stability: Reconstituted antibody is stable for 1 month when stored at 4°C and for 1 year when aliquoted and stored at -20 °C. Avoid repeated freeze-thaw cycles.

    Caution:

    • Avoid repeated freeze-thaw cycles

DOCUMENTS

Documents

Anti-hVISTA-hIgG1fut

Technical Data Sheet

Validation Data Sheet

Safety Data Sheet

Certificate of analysis

Need a CoA ?

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?